vs
ANI PHARMACEUTICALS INC（ANIP）与PROGRESS SOFTWARE CORP（PRGS）财务数据对比。点击上方公司名可切换其他公司
PROGRESS SOFTWARE CORP的季度营收约是ANI PHARMACEUTICALS INC的1.0倍（$252.7M vs $247.1M），ANI PHARMACEUTICALS INC净利率更高（11.1% vs 10.2%，领先0.9%），ANI PHARMACEUTICALS INC同比增速更快（29.6% vs 17.5%），PROGRESS SOFTWARE CORP自由现金流更多（$59.9M vs $29.1M），过去两年ANI PHARMACEUTICALS INC的营收复合增速更高（34.1% vs 17.0%）
ANI制药是一家总部位于美国的特种制药企业，专注于研发、生产和销售仿制药及品牌处方药，核心产品覆盖皮肤科、肿瘤、中枢神经系统治疗、抗感染等领域，主要服务美国境内的医疗机构、零售药房和患者群体。
Progress Software是全球领先的企业级软件服务商，主营应用开发平台、数据连接工具、数字体验解决方案等产品，服务覆盖金融、医疗、制造、零售等多行业的全球企业客户，助力客户搭建高性能可扩展的业务应用，提升运营效率。
ANIP vs PRGS — 直观对比
营收规模更大
PRGS
是对方的1.0倍
$247.1M
营收增速更快
ANIP
高出12.1%
17.5%
净利率更高
ANIP
高出0.9%
10.2%
自由现金流更多
PRGS
多$30.8M
$29.1M
两年增速更快
ANIP
近两年复合增速
17.0%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $247.1M | $252.7M |
| 净利润 | $27.5M | $25.7M |
| 毛利率 | — | 81.6% |
| 营业利润率 | 14.1% | 15.2% |
| 净利率 | 11.1% | 10.2% |
| 营收同比 | 29.6% | 17.5% |
| 净利润同比 | 367.5% | 2144.6% |
| 每股收益（稀释后） | $1.14 | $0.59 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ANIPPRGS
| Q4 25 | $247.1M | $252.7M | ||
| Q3 25 | $227.8M | $249.8M | ||
| Q2 25 | $211.4M | $237.4M | ||
| Q1 25 | $197.1M | $238.0M | ||
| Q4 24 | $190.6M | $215.0M | ||
| Q3 24 | $148.3M | $178.7M | ||
| Q2 24 | $138.0M | $175.1M | ||
| Q1 24 | $137.4M | $184.7M |
净利润ANIPPRGS
| Q4 25 | $27.5M | $25.7M | ||
| Q3 25 | $26.6M | $19.4M | ||
| Q2 25 | $8.5M | $17.0M | ||
| Q1 25 | $15.7M | $10.9M | ||
| Q4 24 | $-10.3M | $1.1M | ||
| Q3 24 | $-24.2M | $28.5M | ||
| Q2 24 | $-2.3M | $16.2M | ||
| Q1 24 | $18.2M | $22.6M |
毛利率ANIPPRGS
| Q4 25 | — | 81.6% | ||
| Q3 25 | — | 81.0% | ||
| Q2 25 | — | 80.1% | ||
| Q1 25 | — | 80.6% | ||
| Q4 24 | — | 83.0% | ||
| Q3 24 | — | 83.7% | ||
| Q2 24 | — | 81.7% | ||
| Q1 24 | — | 82.2% |
营业利润率ANIPPRGS
| Q4 25 | 14.1% | 15.2% | ||
| Q3 25 | 15.9% | 17.6% | ||
| Q2 25 | 6.6% | 16.3% | ||
| Q1 25 | 13.3% | 13.6% | ||
| Q4 24 | -2.3% | 10.0% | ||
| Q3 24 | -13.8% | 22.6% | ||
| Q2 24 | 3.7% | 15.5% | ||
| Q1 24 | 14.8% | 19.0% |
净利率ANIPPRGS
| Q4 25 | 11.1% | 10.2% | ||
| Q3 25 | 11.7% | 7.8% | ||
| Q2 25 | 4.0% | 7.2% | ||
| Q1 25 | 8.0% | 4.6% | ||
| Q4 24 | -5.4% | 0.5% | ||
| Q3 24 | -16.3% | 15.9% | ||
| Q2 24 | -1.7% | 9.2% | ||
| Q1 24 | 13.2% | 12.3% |
每股收益（稀释后）ANIPPRGS
| Q4 25 | $1.14 | $0.59 | ||
| Q3 25 | $1.13 | $0.44 | ||
| Q2 25 | $0.36 | $0.39 | ||
| Q1 25 | $0.69 | $0.24 | ||
| Q4 24 | $-0.45 | $0.01 | ||
| Q3 24 | $-1.27 | $0.65 | ||
| Q2 24 | $-0.14 | $0.37 | ||
| Q1 24 | $0.82 | $0.51 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $285.6M | $94.8M |
| 总债务越低越好 | — | $1.4B |
| 股东权益账面价值 | $540.7M | $478.3M |
| 总资产 | $1.4B | $2.5B |
| 负债/权益比越低杠杆越低 | — | 2.93× |
8季度趋势，按日历期对齐
现金及短期投资ANIPPRGS
| Q4 25 | $285.6M | $94.8M | ||
| Q3 25 | $262.6M | $99.0M | ||
| Q2 25 | $217.8M | $102.0M | ||
| Q1 25 | $149.8M | $124.2M | ||
| Q4 24 | $144.9M | $118.1M | ||
| Q3 24 | $145.0M | $232.7M | ||
| Q2 24 | $240.1M | $190.4M | ||
| Q1 24 | $228.6M | $133.2M |
总债务ANIPPRGS
| Q4 25 | — | $1.4B | ||
| Q3 25 | — | $1.4B | ||
| Q2 25 | — | $1.5B | ||
| Q1 25 | — | $1.5B | ||
| Q4 24 | — | $1.5B | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
股东权益ANIPPRGS
| Q4 25 | $540.7M | $478.3M | ||
| Q3 25 | $505.8M | $477.7M | ||
| Q2 25 | $436.8M | $452.7M | ||
| Q1 25 | $418.6M | $431.8M | ||
| Q4 24 | $403.7M | $438.8M | ||
| Q3 24 | $405.9M | $425.6M | ||
| Q2 24 | $455.8M | $401.7M | ||
| Q1 24 | $452.0M | $461.7M |
总资产ANIPPRGS
| Q4 25 | $1.4B | $2.5B | ||
| Q3 25 | $1.4B | $2.4B | ||
| Q2 25 | $1.3B | $2.4B | ||
| Q1 25 | $1.3B | $2.5B | ||
| Q4 24 | $1.3B | $2.5B | ||
| Q3 24 | $1.3B | $1.6B | ||
| Q2 24 | $920.8M | $1.6B | ||
| Q1 24 | $914.5M | $1.5B |
负债/权益比ANIPPRGS
| Q4 25 | — | 2.93× | ||
| Q3 25 | — | 2.97× | ||
| Q2 25 | — | 3.22× | ||
| Q1 25 | — | 3.50× | ||
| Q4 24 | — | 3.48× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $30.4M | $62.8M |
| 自由现金流经营现金流 - 资本支出 | $29.1M | $59.9M |
| 自由现金流率自由现金流/营收 | 11.8% | 23.7% |
| 资本支出强度资本支出/营收 | 0.5% | 1.1% |
| 现金转化率经营现金流/净利润 | 1.10× | 2.44× |
| 过去12个月自由现金流最近4个季度 | $171.4M | $229.5M |
8季度趋势，按日历期对齐
经营现金流ANIPPRGS
| Q4 25 | $30.4M | $62.8M | ||
| Q3 25 | $44.1M | $73.4M | ||
| Q2 25 | $75.8M | $30.0M | ||
| Q1 25 | $35.0M | $68.9M | ||
| Q4 24 | $15.9M | $19.7M | ||
| Q3 24 | $12.5M | $57.7M | ||
| Q2 24 | $17.4M | $63.7M | ||
| Q1 24 | $18.3M | $70.5M |
自由现金流ANIPPRGS
| Q4 25 | $29.1M | $59.9M | ||
| Q3 25 | $38.0M | $72.4M | ||
| Q2 25 | $71.8M | $29.5M | ||
| Q1 25 | $32.5M | $67.7M | ||
| Q4 24 | $13.5M | $16.8M | ||
| Q3 24 | $7.7M | $56.6M | ||
| Q2 24 | $13.0M | $62.7M | ||
| Q1 24 | $13.7M | $70.2M |
自由现金流率ANIPPRGS
| Q4 25 | 11.8% | 23.7% | ||
| Q3 25 | 16.7% | 29.0% | ||
| Q2 25 | 34.0% | 12.4% | ||
| Q1 25 | 16.5% | 28.4% | ||
| Q4 24 | 7.1% | 7.8% | ||
| Q3 24 | 5.2% | 31.7% | ||
| Q2 24 | 9.4% | 35.8% | ||
| Q1 24 | 10.0% | 38.0% |
资本支出强度ANIPPRGS
| Q4 25 | 0.5% | 1.1% | ||
| Q3 25 | 2.7% | 0.4% | ||
| Q2 25 | 1.9% | 0.2% | ||
| Q1 25 | 1.3% | 0.5% | ||
| Q4 24 | 1.3% | 1.3% | ||
| Q3 24 | 3.2% | 0.6% | ||
| Q2 24 | 3.2% | 0.5% | ||
| Q1 24 | 3.3% | 0.2% |
现金转化率ANIPPRGS
| Q4 25 | 1.10× | 2.44× | ||
| Q3 25 | 1.66× | 3.78× | ||
| Q2 25 | 8.87× | 1.76× | ||
| Q1 25 | 2.23× | 6.30× | ||
| Q4 24 | — | 17.13× | ||
| Q3 24 | — | 2.03× | ||
| Q2 24 | — | 3.93× | ||
| Q1 24 | 1.00× | 3.11× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ANIP
| Sales Of Cortrophin Gel | $111.4M | 45% |
| Sales Of Generic Pharmaceutical Products | $100.8M | 41% |
| Sales Of ILUVIEN And YUTIQ | $19.8M | 8% |
| Sales Of Established Brands | $12.3M | 5% |
| Unapproved Products | $6.5M | 3% |
| Sales Of Royalties And Other Pharmaceutical Services | $2.7M | 1% |
PRGS
| Maintenanceand Services | $187.5M | 74% |
| Share File Acquisition | $67.5M | 27% |
